Circular Genomics
Circular Genomics is a private diagnostics company that develops blood-based circular RNA biomarker tests for neurological and psychiatric conditions, selling primarily through a provider-portal channel serving psychiatrists, neurologists, and primary-care physicians with its MindLight SSRI-response test, while also developing circRNA-based Alzheimer's and multiple sclerosis assays for biopharma partners.
- Company typePrivate
- Founded2021
- HeadquartersAlbuquerque, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Circular Genomics does
Circular Genomics is a private clinical-stage diagnostics company, founded in 2021 and headquartered in San Diego, California, that develops blood-based diagnostic tests leveraging circular RNA (circRNA) biomarkers for neurological and psychiatric conditions. The company's underlying science posits that circRNAs are brain-enriched, degradation-resistant molecules capable of crossing the blood-brain barrier, providing what the company describes as a real-time window into brain biology that single-analyte protein biomarkers cannot capture. Circular Genomics operates a CLIA- and CAP-accredited laboratory and runs a direct-to-provider sales model in which licensed healthcare providers (psychiatrists, neurologists, and primary care physicians) order tests through a web-based Provider Portal, patients provide blood samples at the point of care or laboratory service center, and the company returns results in 3–5 days.
The company's commercial product is MindLight, launched in 2024, a laboratory-developed test that predicts whether patients with major depressive disorder will respond to SSRI antidepressants; validation metrics include 77% positive predictive value, 77% negative predictive value, and a 3.4x higher response likelihood for high-likelihood patients. Its discovery platform, CircPATH (introduced in 2026 alongside a Nature Medicine publication), targets early detection and risk stratification of Alzheimer's disease, with reported AUC of 0.945 and 61% stronger disease-progression predictive power than pTau217 across nearly 2,400 individuals. Circular Genomics pursues two customer segments: (i) individual healthcare providers treating depression or neurodegenerative disease, billed on a per-test basis with HSA/FSA-accepted payment, and (ii) pharmaceutical and biopharma companies seeking biomarkers for clinical-trial enrichment, patient stratification, and companion-diagnostic co-development. Biopharma engagement is anchored by exclusive IP licenses from Washington University in St. Louis and Max Delbrück Center, and by 2026 strategic alliances with Vitazi.ai (multimodal retinal-imaging-plus-blood workflow), Decode Health (AI-enabled multiple sclerosis biomarkers), and the Global Alzheimer's Platform Foundation (Bio-Hermes-001 cohort analysis). The company has raised approximately $28 million in cumulative funding, including a $15 million Series A closed in December 2025 led by Mountain Group Partners.
Circular Genomics firmographics
Firmographics- Name
- Circular Genomics
- Legal name
- Circular Genomics, Inc.
- Website
- https://circulargenomics.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Circular Genomics is a private diagnostics company that develops blood-based circular RNA biomarker tests for neurological and psychiatric conditions, selling primarily through a provider-portal channel serving psychiatrists, neurologists, and primary-care physicians with its MindLight SSRI-response test, while also developing circRNA-based Alzheimer's and multiple sclerosis assays for biopharma partners.
- Ownership category
- akta.pro rank
Circular Genomics industry classification
Industry- Product category
- Molecular Diagnostics
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)
- akta.pro secondary industries
- Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)
Keywords
Where Circular Genomics is headquartered
LocationHeadquarters
- HQ city
- Albuquerque
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Circular Genomics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Laboratory Diagnostic Testing: Circular Genomics generates revenue through laboratory-developed tests (LDTs) performed in its CLIA- and CAP-accredited laboratory. Healthcare providers order tests (e.g., MindLight Antidepressant Response Test) through the Provider Portal, patients provide blood samples at physician offices or lab service centers, and the company processes samples and delivers results to ordering clinicians. Revenue is earned per test transaction.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | MindLight Antidepressant Response Test - single test for MDD patients |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels6 records
Circular Genomics product offering
Product offeringCore offering
Circular Genomics develops and commercializes blood-based diagnostic tests that leverage circular RNA (circRNA) biomarkers for neurological and psychiatric conditions. Its flagship product, MindLight, is a laboratory-developed test predicting SSRI antidepressant response in major depressive disorder patients. The company also operates the CircPATH discovery platform for early detection and risk stratification of Alzheimer's disease and offers circRNA-based biomarker solutions for biopharma clinical trial enrichment.
Product overview
Circular Genomics offers a platform-plus-products architecture centered on circular RNA (circRNA) blood biomarkers for neurological and psychiatric precision medicine. The commercially available MindLight Antidepressant Response Test is their flagship LDT product for predicting SSRI response in depression patients. The CircPATH discovery platform supports Alzheimer's disease diagnostics and drug development. The company is also developing circRNA-based tests for bipolar disorder and Parkinson's disease.
Differentiator
Problem solved
Functional benefit
Brands
- MindLight: Circular RNA-based antidepressant response test that predicts whether patients with major depressive disorder will respond to SSRI treatment. First commercially available product from Circular Genomics.
Products and services
- MindLight Antidepressant Response Test The first commercially available circular RNA-based diagnostic test that predicts whether patients with major depressive disorder (MDD) will respond to SSRI antidepressant treatment. Achieves 77% PPV and 77% NPV in clinical validation studies (EMBARC and ANTARES).
- CircPATH Platform A proprietary circular RNA discovery platform for early detection and risk stratification of Alzheimer's disease, demonstrated AUC of 0.945 for AD detection and 61% stronger predictive power for disease progression versus pTau217. Supports biopharma clinical trial enrichment and patient stratification.
Quantifiable outcome
- AUC of 0.945 for detecting Alzheimer's disease vs. pTau217 gold standard
- +4 more outcomes
Companies that use Circular Genomics
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles3 records
Circular Genomics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
Circular Genomics partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core.
- Global Alzheimer's Platform FoundationcoreStrategic collaboration to analyze samples from the Bio-Hermes-001 study (over 1,000 community-based participants, 24% from underrepresented communities) for circular RNA biomarkers to advance Alzheimer's disease diagnosis, prognosis, and treatment. The partnership aims to validate circRNA signatures as clinical tools for precision medicine in AD and related dementias.
- Decode HealthcoreResearch collaboration focused on circular RNA biomarkers to advance earlier detection and monitoring of multiple sclerosis. Combines Circular Genomics' circular RNA platform with Decode Health's NIH-funded MS biomarker program and cloud-native AI discovery platform to identify circRNA signatures enabling earlier MS detection and more timely treatment decisions.
- Vitazi.aicoreStrategic alliance to jointly develop a multimodal diagnostic workflow combining AI-powered retinal imaging (from Vitazi.ai's oculomics platform) with Circular Genomics' proprietary circular RNA blood biomarkers for early detection and risk stratification of Alzheimer's disease. The two-step clinical workflow uses non-invasive retinal imaging for population-level screening followed by blood-based circRNA molecular confirmation to identify early-stage patients.
- Washington University in St. LouiscoreExclusive IP licensing agreement granting Circular Genomics exclusive commercial rights to circRNA biomarkers for Alzheimer's disease, covering foundational IP for identification, measurement, and clinical application of circRNA biomarkers across the entire AD continuum from preclinical to symptomatic stages.
- Max Delbrück CentercoreExclusive IP licensing agreement granting Circular Genomics exclusive commercial rights to circRNA biomarkers for Alzheimer's disease, complementing the Washington University license to significantly expand the company's proprietary IP estate in neurodegenerative disease diagnostics.
Scale indicators6 records
Recent moves6 records
Expansion highlights6 records
Circular Genomics competitors and assessment
Company assessmentDirect peers
- C2N Diagnostics: C2N Diagnostics is the closest direct peer: it markets PrecivityAD and PrecivityAD2, blood-based pTau217/Aβ tests for early Alzheimer's detection performed in its CLIA-certified lab. It competes head-to-head with Circular Genomics' CircPATH for AD biomarker adoption by neurologists and biopharma trial sponsors.
- Quanterix: Quanterix commercializes the Simoa ultra-sensitive biomarker platform and offers proprietary blood-based neurology assays (including pTau217) used in clinical research and pharma services. Comparable in addressing neurological biomarker discovery with a different (Simoa immunoassay) technology approach.
- Myriad Genetics (GeneSight): Myriad's GeneSight is a pharmacogenomic test that helps psychiatrists select antidepressants - directly comparable to Circular Genomics' MindLight in use case (predicting SSRI response in MDD) and sales motion (psychiatrist-targeted). GeneSight is the market leader MindLight must displace in precision psychiatry.
- Genomind: Genomind offers the Professional PGx Express test for mental health medication selection, including antidepressants and antipsychotics. Direct competition with MindLight in the precision psychiatry category with established psychiatrist relationships.
Emerging players
- ALZpath: ALZpath is an emerging diagnostics company developing proprietary pTau217 antibody-based assays for early Alzheimer's detection, with a focused AD-only portfolio similar in scope to Circular Genomics' CircPATH. Direct head-to-head competition in AD biomarker development with similar size and stage.
- Sengenics: Sengenics provides protein microarray-based biomarker discovery and immunogenicity profiling services with applications in neurology and immunology. Comparable as a biomarker discovery platform serving biopharma translational research, though Sengenics focuses on protein arrays rather than circRNA.
Broad incumbents
- Roche Diagnostics (Elecsys): Roche Diagnostics operates the Elecsys platform for CSF and plasma AD biomarker assays (pTau181, pTau217, Aβ42/40). As a broad incumbent, Roche competes on installed immunoassay infrastructure and global clinical reach rather than on a focused circRNA-based biomarker offering.
- Fujirebio: Fujirebio manufactures the Lumipulse G pTau217/β-Amyloid 1-42 plasma ratio assay, an FDA-cleared blood-based AD diagnostic. Direct competition with CircPATH on standard-of-care neurology adoption, but from a much larger diagnostics incumbent with broader immunoassay menus.
- Bio-Rad Laboratories: Bio-Rad supplies life science research and clinical diagnostic products, including quality controls, reagents, and instruments used in molecular and proteomic biomarker workflows. Adjacent incumbent that supplies the broader ecosystem in which circRNA-based diagnostics operate.
Others
- Mindera Health: Mindera Health is a precision diagnostics company commercializing a skin biopsy-based molecular test for psoriasis. Not a direct competitor but a peer precision-diagnostics commercialization model; Mindera Health's CEO Ron Rocca also serves on Circular Genomics' board.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Circular Genomics social profiles
Digital presenceCircular Genomics compliance and trust
Trust signalCompliance2 records
Circular Genomics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Circular Genomics leadership team
Management profileNumber of profiles
Profiles14 records
Circular Genomics funding detail
Funding detailFunding overview
Funding rounds5 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Circular Genomics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Circular Genomics
What does Circular Genomics do?
Circular Genomics develops and commercializes blood-based diagnostic tests that leverage circular RNA (circRNA) biomarkers for neurological and psychiatric conditions. Its flagship product, MindLight, is a laboratory-developed test predicting SSRI antidepressant response in major depressive disorder patients. The company also operates the CircPATH discovery platform for early detection and risk stratification of Alzheimer's disease and offers circRNA-based biomarker solutions for biopharma clinical trial enrichment.
Is Circular Genomics a public or private company?
Circular Genomics is a private company. It is classified as venture growth investor backed and is currently operating.
When was Circular Genomics founded?
Circular Genomics was founded in 2021. It employs 11 to 50 people.
Where is Circular Genomics based?
Circular Genomics is headquartered in Albuquerque, United States, in the North America region.
How does Circular Genomics make money?
One revenue line is on record: laboratory Diagnostic Testing.
Who are Circular Genomics's main competitors?
Direct peers on record are C2N Diagnostics, Quanterix, Myriad Genetics (GeneSight) and Genomind. Emerging players are ALZpath and Sengenics. Broad incumbents are Roche Diagnostics (Elecsys), Fujirebio and Bio-Rad Laboratories. Mindera Health is listed as an others.
Does Circular Genomics have an API?
No public API is recorded for Circular Genomics.
What industry is Circular Genomics in?
Circular Genomics's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAFAMAE, Molecular Diagnostics & Genomics Laboratories, with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 621511 and its SIC code is 8071.